| DB ID | MyCo_6007 |
| Title | Levels of (1→3)-β-D-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species |
| Year | 2010 |
| PMID | 20923575 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | Pediatric Cancer Patients |
| Genus | Candida |
| Species | glabrata |
| Organism | Candida glabrata |
| Ethical Statement | The study was approved by the Ethics Committees of the Faculty of Medicine, Kuwait University and Ministry of Health, Kuwait. Informed consent of the patients was obtained before collecting the clinical samples. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Candida mannan |
| Biomarker Full Name | Candida mannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Kuwait |
| Cohort | The study was carried out in a tertiary care Pediatric Cancer Ward, Al-Sabah Hospital, Kuwait between July 1, 2007 to December 31, 2008. Sixty-three cancer patients, 57 (90%) with acute lymphoblastic leukemia (ALL) and 6 (10%) with acute myeloid leukemia (AML) were followed-up by weekly surveillance cultures for varying periods for assessing the extent of Candida colonization. Forty-five patients were males. Their age ranged from 1 to 16 years. A child was considered as colonized if Candida sp. was isolated from one or more anatomic sites. A patient yielding Candida sp. on repeat cultures at least from one site was considered as persistently colonized. |
| Cohort No. | 63 |
| Age Group | Jan-16 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The incidence of fungal infections among cancer patients has shown a steady increase in recent years. This may partly be attributed to the use of more aggressive chemotherapeutic regimens, resulting in more prolonged survival of these immunosuppressed patients while they continue to remain vulnerable to invasive fungal infections. Although establishing an early diagnosis for invasive mycoses is ideal for timely administration of specific antifungal therapy, it invariably gets delayed due to want of culture or histopathologic evidence. |
| Technique | Immunological assay |
| Analysis Method | Platelia Candida Ag. Assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Platelia Candida Ag. Assay |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
